3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
9
gadolinium ethoxybenzyl DTPA
4
Hepatectomy
4
lenvatinib
3
entecavir
3
Sufentanil
3
Ribavirin
3
Propranolol
3
Lamivudine
3
sofosbuvir-velpatasvir drug combination
2
peginterferon alfa-2a
2
gadoterate meglumine
2
atezolizumab
2
Thrombectomy
2
Tenofovir
2
Sevoflurane
2
Radiofrequency Ablation
2
Laparoscopy
2
Esketamine
2
Chemoembolization, Therapeutic
2
Bevacizumab
2
xihuang
1
stronger neominophagen C
1
ledipasvir
1
huaier
1
halofantrine
1
gadoteridol
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma, Hepatocellular
×
Neuropsychological Tests
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled